Sosei and Vectura Announce Start of Phase II Clinical Study with NVA237 in the USA
The trial, a randomised, double-blind, placebo-controlled, parallel group, multi-centre study will assess the safety of 28 days treatment of NVA237 in patients with moderate to severe COPD. NVA237 was licensed to Novartis by Sosei and Vectura in 2005 in a deal in which the two companies could receive up to US$ 375 million in milestones as well as royalties on product sales. NDA submissions are expected to be filed in 2010 for both NVA237 and the combination product with indacaterol known as QVA149.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.